01—Abstract
Summary
Summary of the 8-K filed October 13, 2026. Cited figures are marked; the original filing is the authoritative source.
STERIS plc (STE) disclosed on October 11, 2026 that its wholly owned subsidiary, STERIS Corporation ("Purchaser"), entered into a Purchase and Sale Agreement to acquire all equity interests of Xodus Medical, Inc., a specialty surgical products business based in Pennsylvania, and certain related affiliates, from the Kaforey family sellers.
The purchase price is $2.1 billiona in cash at closing, subject to customary adjustments, plus up to $150 million of additional earnout consideration tied to specified post-closing performance targets in calendar 2028. The Acquisition is expected to be financed primarily with debt and is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals. In connection with the deal, STERIS and Purchaser entered into a bridge financing commitment with JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA for up to $2.0 billion in aggregate senior unsecured bridge facilities.
The commitment may be reduced dollar-for-dollar by net proceeds from permanent financing or asset sales before or after closing. Either party may terminate the Purchase Agreement if the Acquisition has not occurred by July 12, 2027, extendable in certain circumstances to January 11, 2028. The filing identifies regulatory approval risk and the ability to realize expected cost savings, tax benefits and synergies as key risks, alongside the increased indebtedness that the debt-financed deal will add.
02—Key points
Key Highlights
- Acquisition of Xodus Medical, Inc., a Pennsylvania-based specialty surgical products business, for $2.1 billion in cash at closing, subject to customary adjustments
- Up to $150 million of additional earnout consideration based on specified post-closing performance targets in calendar 2028
- Acquisition expected to be financed primarily with debt and anticipated to close by December 31, 2026
- Bridge financing commitment from JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA of up to $2.0 billion in senior unsecured bridge facilities
- Bridge commitment reducible dollar-for-dollar by net proceeds from permanent financing or asset sales before or after closing
- Outside date of July 12, 2027, extendable in certain circumstances to January 11, 2028
- Closing is subject to customary conditions, including receipt of requisite regulatory approvals
03—Questions
Frequently Asked Questions
What is STERIS acquiring and for how much?
STERIS Corporation, a wholly owned subsidiary of STERIS plc, agreed to acquire all equity interests of Xodus Medical, Inc., a specialty surgical products business based in Pennsylvania, and certain related affiliates for $2.1 billion in cash at closing, subject to customary adjustments, plus up to $150 million of earnout consideration tied to calendar 2028 performance targets.
How will the acquisition be funded?
The filing states the Acquisition is expected to be financed primarily with debt. STERIS and its subsidiary also obtained a bridge financing commitment of up to $2.0 billion from JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA, which can be reduced dollar-for-dollar by net proceeds from permanent financing or asset sales.
When is the transaction expected to close and what could prevent it?
The Acquisition is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals. Either party may terminate the agreement if the deal has not closed by July 12, 2027, which may be extended in certain circumstances to January 11, 2028.
What risks does the filing identify for the acquisition?
The filing cites the risk that required regulatory approvals may not be received, may take longer than expected or may impose adverse conditions, and that expected cost savings, tax benefits and other synergies may not be realized or may take longer than expected. It also flags increased indebtedness limiting financial flexibility or increasing future borrowing costs, and possible unknown liabilities or integration difficulties.
04—Continue